Onconetix, Inc.
Onconetix develops Proclarix, an in vitro diagnostic test for prostate cancer approved in the European Union.
10-QNov 16Latest SEC filing
Nov 5Latest story
Onconetix develops Proclarix, an in vitro diagnostic test for prostate cancer approved in the European Union.
November 2026
October 2026
August 2026
July 2026